Harmony Biosciences Reports Record Q2 2026 Revenue, Shares Positive BP-205 Phase 1 Data
PLYMOUTH MEETING, Pa., August 4, 2026 Harmony Biosciences reported record second-quarter 2026 net revenue of $261.3 million for WAKIX®...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
PLYMOUTH MEETING, Pa., August 4, 2026 Harmony Biosciences reported record second-quarter 2026 net revenue of $261.3 million for WAKIX®...
